SubsidieMeestersMIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care
MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.
Projectdetails
Introduction
Imagine a future where the limitless possibilities of virtual biopsies in cancer diagnostics can be explored. A future in which cancer patients would have access to MRI-enabled virtual biopsies in order to receive the best possible treatment decisions anywhere on the globe.
Project Overview
MIRACLE is developing a first-of-its-kind add-on device for MRI scanners that will be used to acquire a virtual biopsy of the tumor. This device will provide not only structural information on tumor dimensions for (tissue conserving) surgery but also unique metabolic information on the efficacy of specific systemic therapies.
Ultimately, this fully non-invasive, accurate, and rapid predictive approach can guide patients to the best fitting treatment plan given their personal circumstances and tumor characteristics.
Collaboration and Development
WaveTronica (WT), together with the University Medical Centre Utrecht (UMCU), German Cancer Research Centre (DKFZ), and Medical University of Lublin (UMLUB), aim to build this future by bringing the first Metabolic MRI-as-a-Service solution to the market.
Past projects and research led to the development of a Proof-of-Concept MRI coil capable of detecting metabolic biomarkers non-invasively using the strongest clinically available MRI system. This was demonstrated in:
- FET-OPEN-01-2016-2017-801075 - the Non-Invasive-Chemistry-Imaging (NICI)
- FET-OPEN-03-2018-2019-2020 - FET Innovation Launchpad - MIRACLE
The MRI coil is a plug-and-play add-on for existing MRI machines, resulting in an accessible and affordable virtual biopsy tool that can identify cancer biomarkers and tumor activity without shedding a drop of patient blood.
Service Transformation
This project converts a complex research tool into an accessible diagnostic service (Metabolic MRI-as-a-Service). MIRACLE is supported by the Dutch reimbursement company VGZ, Tesla DC, and oncologists, showing there is a strong market demand.
Next Steps
Now the challenge lies in bringing the breast coil PoC hardware and software to the next level using breast cancer as a use case.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.495.127 |
| Totale projectbegroting | € 2.498.128 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- WAVETRONICA BVpenvoerder
- DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
- UNIWERSYTET MEDYCZNY W LUBLINIE
- UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic InterventionsMITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs. | EIC Transition | € 2.100.238 | 2022 | Details |
Early detection of treatment response in breast cancerThe project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects. | EIC Transition | € 2.499.229 | 2024 | Details |
Truly portable MRI for extremity and brain imaging anywhere & everywhereThe NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally. | EIC Transition | € 2.494.415 | 2023 | Details |
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid TumoursScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027. | EIC Transition | € 2.499.911 | 2025 | Details |
Prostate Cancer Diagnosis, Localisation and Characterisation using UltrasoundPCaVision aims to enhance prostate cancer diagnosis using cost-effective ultrasound imaging and algorithms, improving patient access and reducing healthcare costs across 16 EU clinics. | EIC Transition | € 1.950.000 | 2022 | Details |
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions
MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.
Early detection of treatment response in breast cancer
The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.
Truly portable MRI for extremity and brain imaging anywhere & everywhere
The NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally.
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Prostate Cancer Diagnosis, Localisation and Characterisation using Ultrasound
PCaVision aims to enhance prostate cancer diagnosis using cost-effective ultrasound imaging and algorithms, improving patient access and reducing healthcare costs across 16 EU clinics.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Revealing liver micrometastases in vivo using ultra-high definition MRIMicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights. | ERC Starting... | € 1.998.456 | 2025 | Details |
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRIDevelop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics. | ERC Starting... | € 1.497.669 | 2024 | Details |
Hyperpolarized Magnetic Resonance at the point-of-careHYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods. | ERC Starting... | € 1.499.968 | 2024 | Details |
Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolismGLUCO-SCAN aims to develop and clinically evaluate a novel whole-body deuterium metabolic imaging (DMI) method for cancer assessment, overcoming PET's limitations and enabling widespread screening. | ERC Consolid... | € 2.495.924 | 2023 | Details |
Ontwikkeling Tumor Lokalisatie Systeem voor Borstkanker (MaMaLoc)Sirius Medical Systems en 3T ontwikkelen een magnetische tumor lokalisatietechniek die chirurgen helpt bij het vroegtijdig verwijderen van tumoren, met verbeterde zorg en economische groei als resultaat. | Mkb-innovati... | € 84.000 | 2018 | Details |
Revealing liver micrometastases in vivo using ultra-high definition MRI
MicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights.
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI
Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.
Hyperpolarized Magnetic Resonance at the point-of-care
HYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods.
Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism
GLUCO-SCAN aims to develop and clinically evaluate a novel whole-body deuterium metabolic imaging (DMI) method for cancer assessment, overcoming PET's limitations and enabling widespread screening.
Ontwikkeling Tumor Lokalisatie Systeem voor Borstkanker (MaMaLoc)
Sirius Medical Systems en 3T ontwikkelen een magnetische tumor lokalisatietechniek die chirurgen helpt bij het vroegtijdig verwijderen van tumoren, met verbeterde zorg en economische groei als resultaat.